{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+blood+samples+for+serum+biomarkers+of+immune+response",
    "query": {
      "intervention": "Serum blood samples for serum biomarkers of immune response"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 18,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+blood+samples+for+serum+biomarkers+of+immune+response&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T02:06:21.975Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02107755",
      "title": "Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Metastases",
        "Lung Metastases",
        "Recurrent Melanoma",
        "Stage IV Melanoma",
        "Tumors Metastatic to Brain"
      ],
      "interventions": [
        {
          "name": "ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "stereotactic radiosurgery",
          "type": "RADIATION"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2014-09-05",
      "completion_date": "2021-08-16",
      "has_results": true,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-10-09T02:06:21.975Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02107755"
    },
    {
      "nct_id": "NCT07734467",
      "title": "Immune Response to PSF in Idiopathic vs Neuromuscular Scoliosis",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Posterior Spinal Fusion",
        "Idiopathic Scoliosis",
        "Neuromuscular Scoliosis"
      ],
      "interventions": [
        {
          "name": "Serum blood samples for serum biomarkers of immune response",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Ambrish Patel",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "0 Years to 99 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-10",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-09T02:06:21.975Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07734467"
    },
    {
      "nct_id": "NCT03835533",
      "title": "Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "NKTR-214 (Cohort A)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab (Cohort A, B and C)",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic body radiation therapy (SBRT) (Cohort B)",
          "type": "RADIATION"
        },
        {
          "name": "CDX-301 (Cohort B and C)",
          "type": "DRUG"
        },
        {
          "name": "Poly-ICLC (Cohort B)",
          "type": "DRUG"
        },
        {
          "name": "INO-5151 (Cohort C)",
          "type": "DRUG"
        },
        {
          "name": "Cellectra 2000",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "DEVICE"
      ],
      "sponsor": "Parker Institute for Cancer Immunotherapy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 43,
      "start_date": "2019-06-21",
      "completion_date": "2022-10-03",
      "has_results": true,
      "last_update_posted_date": "2024-04-12",
      "last_synced_at": "2026-10-09T02:06:21.975Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • San Francisco, California • New York, New York + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03835533"
    },
    {
      "nct_id": "NCT06737380",
      "title": "UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SLE",
        "Lupus",
        "Systemic Lupus Erthematosus",
        "Systemic Lupus Erythematosus",
        "Systemic Lupus Erythematosus (SLE)"
      ],
      "interventions": [
        {
          "name": "Physical examination",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Electrocardiogram",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "SF-36 questionnaire",
          "type": "OTHER"
        },
        {
          "name": "Clinical laboratory evaluations - Serology",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Clinical laboratory evaluations - Biochemistry",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Clinical laboratory evaluations - Hematology",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Pregnancy Test",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Urinalysis",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "SLE activity evaluation",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "SLE biomarker profiling",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Cytokines and chemokine profiling",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "single dose of UC-MSCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PROMIS instruments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "LiveKidney.Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2025-01-07",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-10-09T02:06:21.975Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06737380"
    },
    {
      "nct_id": "NCT03425331",
      "title": "Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-04-10",
      "completion_date": "2021-11-28",
      "has_results": true,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-09T02:06:21.975Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03425331"
    },
    {
      "nct_id": "NCT01134614",
      "title": "Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Melanoma",
        "Metastatic Melanoma",
        "Recurrent Melanoma",
        "Stage III Cutaneous Melanoma AJCC v7",
        "Stage IIIA Cutaneous Melanoma AJCC v7",
        "Stage IIIB Cutaneous Melanoma AJCC v7",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 245,
      "start_date": "2010-12-28",
      "completion_date": "2027-03-19",
      "has_results": true,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-09T02:06:21.975Z",
      "location_count": 257,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • Rancho Mirage, California + 197 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01134614"
    },
    {
      "nct_id": "NCT02408861",
      "title": "Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Anal Carcinoma",
        "HIV Infection",
        "Kaposi Sarcoma",
        "Lung Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Recurrent Classic Hodgkin Lymphoma",
        "Refractory Classic Hodgkin Lymphoma",
        "Unresectable Solid Neoplasm",
        "HIV-associated Cancers"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2015-10-21",
      "completion_date": "2024-08-31",
      "has_results": true,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-10-09T02:06:21.975Z",
      "location_count": 32,
      "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 19 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02408861"
    },
    {
      "nct_id": "NCT01693783",
      "title": "Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Adenocarcinoma",
        "Cervical Squamous Cell Carcinoma",
        "Human Papillomavirus Infection",
        "Recurrent Cervical Carcinoma",
        "Stage IVA Cervical Cancer AJCC v6 and v7",
        "Stage IVB Cervical Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 42,
      "start_date": "2012-12-03",
      "completion_date": "2021-11-24",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-10-09T02:06:21.975Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Sacramento, California • South Pasadena, California + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01693783"
    },
    {
      "nct_id": "NCT02210117",
      "title": "Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Metastatic Kidney Carcinoma",
        "Stage IV Renal Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Metastasectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2014-11-25",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-09T02:06:21.975Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02210117"
    },
    {
      "nct_id": "NCT04197687",
      "title": "TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Adenocarcinoma",
        "Stage II Breast Cancer AJCC v6 and v7",
        "Stage IIA Breast Cancer AJCC v6 and v7",
        "Stage IIB Breast Cancer AJCC v6 and v7",
        "Stage III Breast Cancer AJCC v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Multi-epitope HER2 Peptide Vaccine TPIV100",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 480,
      "start_date": "2020-02-20",
      "completion_date": "2025-01-15",
      "has_results": false,
      "last_update_posted_date": "2023-12-18",
      "last_synced_at": "2026-10-09T02:06:21.975Z",
      "location_count": 30,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04197687"
    }
  ]
}